Resverlogix (TSX:RVX) Tax Provision : C$-0.02 Mil (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Tax Provision?

Resverlogix's tax provision for the three months ended in Mar. 2024 was C$-0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.02 Mil.

Resverlogix Tax Provision Historical Data

The historical data trend for Resverlogix's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Tax Provision Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-0.04

-0.02

Resverlogix Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															-0.01	-	-	-0.01	-

Resverlogix Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.02 Mil.

Resverlogix (TSX:RVX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Executives

Aaron Bradley Cann

Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines